ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025

ALK (ALKB.DC / OMX: ALK B) will publish its results for the first six months of 2025 in the morning on Thursday, 21 August 2025.

Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results for the first six months and the outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. 

Live audio webcast

The meeting will be audio webcasted live and be available for replay on .

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
14/08/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK udnævner Edward Jordan til ny direktør for de kommercielle aktivit...

ALK udnævner Edward Jordan til ny direktør for de kommercielle aktiviteter i Nordamerika ALK (ALKB:DC / OMX: ALK B) har i dag annonceret udnævnelsen af Edward Jordan til ny Executive Vice President (EVP) og direktør for de kommercielle aktiviteter i Nordamerika med virkning fra 5. januar 2026. Edward Jordan afløser Søren Niegel, som midlertidigt har varetaget rollen i forlængelse af beslutningen, gældende fra 1. oktober 2025, om at inkludere ALK's to centrale kommercielle regioner, Europa og Nordamerika, i selskabets topledelse (Executive Leadership Team, ELT) for yderligere at styrke eksek...

December 1, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK appoints Edward Jordan as new EVP and head of Commercial Operation...

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy. Edward Jordan, an A...

December 1, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
11/14/25 November 14, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Nine-month interim report (Q3) 2025 (unaudited) - English version only

Nine-month interim report (Q3) 2025 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på engelsk. ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded.     Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth ra...

November 12, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Nine-month interim report (Q3) 2025 (unaudited)

Nine-month interim report (Q3) 2025 (unaudited) ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded.     Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated. Total revenue inc...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch